ANA Pattern — How to Read Common Antinuclear Antibody Staining Patterns

Sample type: Serum

Other names: ANA pattern, antinuclear antibody pattern, ANA staining pattern, ANA IFA pattern, ANA HEp-2 pattern, nuclear pattern, homogeneous ANA pattern, speckled ANA pattern, nucleolar ANA pattern, centromere ANA pattern, cytoplasmic ANA pattern, mitotic spindle fibers ANA, dense fine speckled, DFS70, ANA titer and pattern

Nuclear, membrane

Staining around the rim of the nucleus. This descriptor does not say whether the staining was smooth or punctate, and that distinction matters: the punctate form (AC-12) is associated with primary biliary cholangitis and may prompt testing for anti-gp210, while the smooth form (AC-11) has uncertain associations based largely on small studies. Ask whether your report specifies which.

Nuclear, centromere

Discrete dots corresponding to chromosome centromeres. This is the one pattern with a particularly restricted antibody target, so it carries more specific information than most. It is associated with limited systemic sclerosis (CREST), primary biliary cholangitis and Sjögren's. If those are suspected, it may prompt testing for anti-CENP-A/B antibodies.

Nuclear, homogenous

Even staining across the nucleus. This pattern is associated with SLE (lupus), drug-induced lupus and juvenile idiopathic arthritis. If those are clinically suspected, it may prompt testing for anti-dsDNA, anti-histone or anti-nucleosome antibodies. The pattern points toward what to test next — it is not a diagnosis on its own, and is read with your titer and symptoms.

Nuclear, nucleolar

Staining concentrated in the nucleoli, associated mainly with systemic sclerosis and its overlap syndromes. This descriptor does not specify which nucleolar sub-pattern was seen, and they point to different tests: homogeneous nucleolar (AC-8) toward anti-Th/To and anti-PM/Scl; clumpy (AC-9) toward anti-fibrillarin/U3-RNP; punctate (AC-10) toward anti-NOR90, and anti-RNA polymerase III if systemic sclerosis is suspected. Ask whether your report specifies the sub-pattern.

Nuclear, proliferating cell nuclear antigen (PCNA), speckled

A variable nuclear staining reflecting antibodies to PCNA, a protein involved in cell division. It has historically been linked with SLE, though it is uncommon and is also reported in other conditions, so it is not specific. If SLE is clinically suspected, anti-PCNA testing may follow. As with every pattern, it is read alongside your titer, symptoms and any antibody-specific results.

Nuclear dots (1-6 per cell)

One to six discrete dots, corresponding to structures called Cajal bodies. This pattern has a low positive predictive value for any disease — meaning it does not point strongly toward a particular diagnosis. It is not, in itself, evidence that disease is absent. The antigens involved (p80-coilin, the SMN complex) have no routine commercial test, so there is usually no confirmatory antibody to order. It is read with your titer and symptoms.

Nuclear dots (6-20 per cell)

Six to twenty discrete dots in the nucleus. What this suggests depends on which antibody is behind it: anti-Sp100 is associated with primary biliary cholangitis, while anti-NXP-2 is associated with dermatomyositis. If either is clinically suspected, the corresponding antibody test may follow. The pattern narrows where to look; it does not decide between them.

Cytoplasmic, cytoskeletal

Filament-like staining through the cytoplasm. This descriptor covers three sub-patterns with different meanings: the linear form (AC-15) is associated with type 1 autoimmune hepatitis, chronic hepatitis C and celiac disease, and may prompt smooth-muscle antibody / F-actin testing if autoimmune hepatitis is suspected; the filamentous form (AC-16) has low predictive value and no routine antigen-specific assay; the segmental form (AC-17) is rare and its clinical relevance remains uncertain. Ask whether your report specifies which.

Cytoplasmic, golgi apparatus

Staining of the Golgi apparatus. Anti-Golgi antibodies have been reported in Sjögren's, SLE and other conditions, but they are not clinically associated with any one autoimmune rheumatic disease, so this pattern is considered non-specific. There is no routine confirmatory test tied to it. It is read in the context of your symptoms rather than treated as a pointer to a particular diagnosis.

Cytoplasmic, lysosomal

A cytoplasmic staining reported by some laboratories that does not correspond to one of the standard ICAP pattern codes. Its clinical significance is not established, and there is no routine confirmatory antibody test tied to it. Read it together with your titer, your symptoms and any specific antibody results, and ask your clinician how your laboratory defines this descriptor.

Cytoplasmic, mitochondrial

A lacy staining throughout the cytoplasm. This is the pattern most strongly tied to a specific condition in the cytoplasmic group: it suggests antimitochondrial antibodies, the serological hallmark of primary biliary cholangitis, a chronic liver condition. It is also seen in systemic sclerosis and PBC overlap. If PBC is suspected, testing for anti-mitochondrial antibodies (AMA-M2) may follow.

Cytoplasmic, ribosomal

A dense fine speckled staining of the cytoplasm, associated with anti-ribosomal P antibodies, which are relatively specific for SLE and are described in neuropsychiatric lupus. This pattern can also reflect antibodies relevant to antisynthetase syndrome or necrotizing myopathy. If SLE or a myositis is clinically suspected, the corresponding antibody test may follow.

Nuclear, Dense Fine Speckled

Fine speckles across the nucleus and the metaphase plate. This pattern is often described as reassuring, but that holds only under three conditions together: it is confirmed as a genuine DFS70 rather than the newer AC-30 look-alike, anti-DFS70 is the only relevant antinuclear antibody found, and clinical suspicion is already low. When all three hold, it can lower suspicion for autoimmune rheumatic disease. The pattern alone is not enough — your clinician confirms it.

Cytoplasmic, Discrete Dots/GW body

Scattered discrete dots in the cytoplasm, corresponding to structures called GW bodies. Autoantibodies with this pattern have been reported across several autoimmune conditions, but their prevalence and significance are not well established, so the finding is of uncertain meaning on its own. It is interpreted alongside your titer, symptoms and any antibody-specific results.

Mitotic, Spindle Fibers

Staining of the spindle apparatus that cells use to divide, seen in cells caught mid-division. This pattern has a low positive predictive value for any disease and is found infrequently. Low predictive value means it does not point strongly toward a particular diagnosis — but it is not evidence that disease is absent. There is usually no routine confirmatory antibody test for it, so it is read together with your titer and symptoms rather than treated, in either direction, as an answer.

Nuclear, Speckled

Scattered speckles across the nucleus, and one of the most common patterns. It is broad: it is associated with SLE, Sjögren's, mixed connective tissue disease, dermatomyositis and overlap syndromes. When a connective-tissue disease is suspected, it typically prompts an ENA panel (anti-SSA/SSB, anti-U1RNP, anti-Sm, anti-Scl-70). Because it is common and non-specific, it also occurs in people without autoimmune disease.

Your ANA (antinuclear antibody) report came back with a pattern — maybe "nuclear, homogeneous," "speckled," "cytoplasmic, reticular/AMA," or something that sounds alarming like "mitotic spindle fibers." The pattern describes how and where the antibodies stained cells under a fluorescent microscope, and it is one of the most confusing parts of any lab report. This page helps you find your exact pattern and understand what it may suggest — and what to confirm next.

The one idea that explains this whole page: the pattern shows where the staining occurred, not what disease you have. It may suggest which specific antibody to confirm next — it does not identify the antibody or diagnose a disease by itself. Read it together with your titer and, above all, your symptoms.

At a glance

  • Two things are reported together: titer and pattern. Titer = the endpoint dilution (a semiquantitative estimate of how much); pattern = where and how the antibodies stained.
  • The pattern may suggest a follow-up test, not a diagnosis — when the clinical context supports it (anti-dsDNA, anti-centromere, and so on). It does not determine automatically which test is ordered.
  • A pattern usually suggests, it does not identify. The centromere pattern is the exception, with a particularly restricted antibody target.
  • A pattern only appears when the screen is positive (at 1:80 or above); a negative screen reports no pattern.
  • A positive ANA happens in healthy people, including at the 1:80 screening dilution — and sometimes at high titer, as with DFS70.
  • More than one pattern may be reported. Quest reports each observed pattern with its corresponding titer; interpret each pattern-titer pair separately.
  • "Mitotic spindle fibers" has low predictive value for any disease — it does not point strongly toward a diagnosis, and it is not evidence that disease is absent.
  • Use the exact pattern name and AC code. Similar-sounding patterns (for example, few vs multiple nuclear dots) point to very different follow-up tests.

How to read your result: titer and pattern together

Your report shows these as separate lines because they are separate results. The screen runs first; if it is positive at 1:80 or above, the lab automatically reports the pattern and its titer. If more than one pattern is seen, each is reported with its own corresponding titer — read each pattern-titer pair separately. A negative screen produces no pattern at all.

The titer is the endpoint dilution — how far the blood was diluted and still showed antibodies (reported up to 1:1,280). On Quest's current workflow 1:80 is the screening dilution, so a 1:80 result is the lowest reported and can occur in healthy people. Higher titers raise suspicion; Quest's interpretation guide describes a titer above 1:160 as high and strongly suggestive of autoimmune disease. The pattern is the shape and location of the staining, which suggests candidate antibody targets. Neither alone is the answer — a high-titer homogeneous pattern in someone with joint pain and rashes means something very different from a low-titer speckled pattern found incidentally, and some patterns (such as dense fine speckled) can be high-titer in healthy people too.

Find your pattern

Patterns are grouped by where in the cell the antibodies stain — the nucleus, the cytoplasm, or structures that appear during cell division (mitotic). The international naming system (ICAP) currently classifies 31 positive patterns, AC-1 through AC-31, plus AC-0 for no detectable staining and AC-XX for unclassified patterns; you may see an AC code on your report. This page covers the common ones. Find your exact pattern — similar-sounding names can point to very different follow-up tests.

Pattern (ICAP code) Where it stains May suggest Possible follow-up if clinically suspected
Homogeneous (AC-1) Nucleus, even SLE, drug-induced lupus, juvenile idiopathic arthritis anti-dsDNA, anti-histone, anti-nucleosome
Dense fine speckled / DFS70 (AC-2) Nucleus, fine speckles + metaphase plate Often seen without autoimmune rheumatic disease when confirmed and monospecific anti-DFS70 (and exclude the AC-30 look-alike)
Centromere (AC-3) Discrete nuclear dots Limited systemic sclerosis (CREST), primary biliary cholangitis, Sjögren's anti-CENP-A/B (restricted target — the one tight pattern)
Speckled (AC-4/5) Nucleus, speckled SLE, Sjögren's, mixed connective tissue disease, dermatomyositis, overlap ENA panel (anti-SSA/SSB, anti-U1RNP, anti-Sm, anti-Scl-70) if a connective-tissue disease is suspected
Multiple nuclear dots (AC-6) 6–20 discrete dots Primary biliary cholangitis or dermatomyositis — depends on the antibody anti-Sp100 (if PBC suspected) or anti-NXP-2 (if dermatomyositis suspected)
Few nuclear dots (AC-7) 1–6 discrete dots Low predictive value for any disease p80-coilin / SMN (research assays; often no clear correlation)
Homogeneous nucleolar (AC-8) Nucleoli, smooth Systemic sclerosis and SSc-overlap anti-Th/To, anti-PM/Scl
Clumpy nucleolar (AC-9) Nucleoli, coarse/clumpy Systemic sclerosis; confirmed anti-fibrillarin is associated with diffuse disease anti-fibrillarin / U3-RNP
Punctate nucleolar (AC-10) Nucleoli, dotted (NOR) Systemic sclerosis or other autoimmune contexts; the pattern does not establish an RNA-polymerase subtype anti-NOR90; anti-RNA polymerase III if systemic sclerosis is suspected
Nuclear envelope, punctate (AC-12) Rim of nucleus, dotted Primary biliary cholangitis anti-gp210
Nuclear envelope, smooth (AC-11) Rim of nucleus, smooth Uncertain; based on small cohorts lamins / LBR (specialized assays)
Cytoplasmic, reticular/AMA (AC-21) Lacy cytoplasm Primary biliary cholangitis (hallmark); also SSc overlap anti-mitochondrial antibodies (AMA-M2)
Cytoplasmic, dense fine speckled (AC-19) Cytoplasm, dense SLE (ribosomal P); antisynthetase syndrome; necrotizing myopathy anti-ribosomal P, anti-tRNA synthetases, anti-SRP
Cytoplasmic, fine speckled (AC-20) Cytoplasm, fine Antisynthetase syndrome, interstitial lung disease, polyarthritis, Raynaud's anti-Jo-1 (AC-20 is not specific for it — confirm if myositis suspected)
Cytoplasmic fibrillar, linear (AC-15) Cytoplasmic filaments Type 1 autoimmune hepatitis, chronic hepatitis C, or celiac disease smooth-muscle antibodies / F-actin if autoimmune hepatitis is suspected
Cytoplasmic fibrillar, filamentous (AC-16) Cytoplasmic filaments Low predictive value; no routine antigen-specific assay (no routine confirmatory test)
Cytoplasmic fibrillar, segmental (AC-17) Cytoplasmic filaments Rare; clinical relevance remains uncertain No routine confirmatory assay; α-actinin and vinculin are candidate antigen associations
Cytoplasmic, discrete dots / GW body (AC-18) Scattered cytoplasmic dots Uncertain; variable associations anti-GW182/Su
Rods and rings (AC-23) Cytoplasmic rods/rings Hepatitis C treated with interferon/ribavirin anti-IMPDH2 (in the HCV-therapy context)
Mitotic spindle fibers (AC-25) Spindle, dividing cells Low predictive value for any disease (no routine confirmatory test; read with symptoms)
Mitotic centrosome (AC-24) Centrosome, dividing cells Low predictive value for any disease (no routine confirmatory test)
Mitotic intercellular bridge (AC-27) Midbody, dividing cells Low predictive value for any disease (no routine confirmatory test)
NuMA-like (AC-26) Nucleus + spindle poles About half have autoimmune features (Sjögren's, SLE, UCTD, limited SSc, RA) read with symptoms; specialized assays

On the speckled row: ICAP permits reporting "nuclear speckled" at the competent level as AC-4/5 grouped, and many reports do exactly that. If your report specifies an exact AC-4 (fine) or AC-5 (large/coarse), the follow-up paths diverge somewhat — bring the exact code to your clinician.

The patterns people ask about most

Mitotic spindle fibers (AC-25). The most-searched pattern, and the key fact is that it has a low positive predictive value for any disease and is found infrequently. It reflects antibodies to the machinery cells use to divide. Low predictive value means it does not point strongly toward a particular diagnosis — but it is not evidence that disease is absent. Your clinician reads it with your titer and symptoms rather than treating the name, in either direction, as an answer.

Cytoplasmic patterns. "Cytoplasmic" describes where the staining appeared — outside the nucleus — not one shared level of risk. Reticular/AMA (AC-21) suggests antimitochondrial antibodies and primary biliary cholangitis, a chronic liver condition. AC-19 can suggest antibodies relevant to SLE, antisynthetase syndrome or necrotizing myopathy; AC-20 can suggest anti-Jo-1, linked to antisynthetase syndrome and interstitial lung disease. So "cytoplasmic" is not one result — use the exact AC code to know which follow-up matters.

Dense fine speckled (DFS70, AC-2). Often discussed as reassuring, but only under three conditions together: the pattern is confirmed as a genuine DFS70 (not the newer AC-30 look-alike), anti-DFS70 is the only relevant antinuclear antibody found, and clinical suspicion is already low. The pattern alone is not enough — your clinician confirms it.

Homogeneous and speckled are the two most common nuclear patterns; see the table above for what each may suggest and the possible follow-up.

Two people, the same "speckled" pattern

Person A has a low-titer (1:80) speckled ANA found on a general work-up, with no symptoms. For her, this is often an incidental finding — a low-titer positive ANA is common in healthy people — and the clinician may decide that no additional antibody testing is warranted.

Person B has a high-titer (1:640) speckled ANA with dry eyes, joint pain, and fatigue for months. Same pattern word, very different weight: here it may prompt specific antibody testing (for example anti-SSA/SSB, anti-U1RNP), and those results with her symptoms may point toward a defined condition.

Same pattern, different meaning — titer and symptoms, not the pattern name alone, carry the weight.

What the pattern cannot tell you

It cannot diagnose a disease. The specific antibody test and your clinical picture do that.

It cannot be read without the titer and your symptoms. A pattern with no context is not interpretable.

It cannot rule autoimmune disease in or out on its own. Positive ANAs occur in healthy people; some people with autoimmune disease have negative or atypical patterns.

Common interpretation mistakes

Reading the pattern as a diagnosis. It shows where the antibodies stained and may suggest what to confirm next — it is not a named disease or an antibody identification.

Being alarmed by a dramatic-sounding pattern. "Mitotic spindle fibers" and many cytoplasmic patterns have low disease significance; the name is not the meaning.

Ignoring the titer. A result at the 1:80 screening dilution is common and often incidental; a higher titer carries more weight.

Assuming a positive ANA means lupus. ANA is positive in many conditions and in healthy people.

Questions your doctor may ask

What is the exact pattern and titer? Both are needed — "positive ANA" alone is not enough.

Do you have symptoms, and for how long? Joint pain, rashes, dry eyes, Raynaud's, and fatigue change how a pattern is weighed.

Are you taking any medications? Some drugs cause a positive ANA (drug-induced lupus), often with a homogeneous pattern.

Read together with

ANA titer — the other half of the result; read with the pattern, never alone.

Specific antibody tests — anti-dsDNA, anti-centromere, anti-SSA/SSB, anti-U1RNP, anti-Scl-70, and others the pattern points toward.

Your symptoms and history — the context that gives any pattern its meaning.

Clinical pearls

The pattern suggests candidate target antigens, which may prompt a follow-up antibody test when the clinical context supports it. Think of it as an orienting step, read with your symptoms — not an endpoint, and not an antibody identification on its own.

There is no single "strength" ranking. The centromere pattern (AC-3) is the one with a particularly restricted antibody target; most patterns suggest a follow-up test rather than a specific answer, and several mitotic and cytoplasmic patterns have low predictive value.

Use the exact AC code. Similar-sounding patterns diverge: few nuclear dots (AC-7, low predictive value) versus multiple nuclear dots (AC-6, PBC or dermatomyositis); dense fine speckled (AC-19, cytoplasmic) versus fine speckled (AC-20, cytoplasmic). "Cytoplasmic" alone is not one result.

DFS70 (AC-2) reassurance is conditional — it requires a confirmed bona fide DFS70 (not the AC-30 look-alike), monospecific anti-DFS70, and low clinical suspicion. The pattern name alone is not enough.

A positive ANA is common in healthy people, at low titer and sometimes high; the result is always read with symptoms.

In one sentence

An ANA staining pattern shows where antibodies bound on HEp-2 cells. It may suggest a follow-up test in the right clinical context, but it does not identify an antibody or diagnose a disease.

The bottom line

Your ANA report pairs a titer (a semiquantitative estimate of how much) with a pattern (where and how the antibodies stained). The pattern shows where the staining occurred and may suggest which antibody to confirm next — it does not identify the antibody or diagnose a disease on its own. The centromere pattern is the one with a tightly restricted target; mitotic spindle fibers and several other patterns have low predictive value, meaning they point weakly toward any diagnosis (not that disease is ruled out). "Cytoplasmic" is not one result — AC-21 suggests primary biliary cholangitis, while AC-19 and AC-20 suggest myositis, antisynthetase syndrome, interstitial lung disease, or SLE. Whatever the pattern, use the exact name and AC code, read it with your titer and symptoms, and bring the report to your clinician, who orders the specific antibody tests the pattern points toward.

Clinical Takeaway Start with the exact pattern name and AC code. The pattern may suggest which antibody to confirm next, but it does not identify an antibody or diagnose a condition by itself. Read it together with your titer and symptoms; your clinician decides whether a follow-up test is warranted in your clinical context.

Ana Pattern (Quest)
Healthmatters dashboard showing biomarker trend graph

Every lab result you’ve ever had, charted and explained.

Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.

Start with my report →
Beyond Ana Pattern (Quest) — 10,000+ markers explained
One Ana Pattern (Quest) result tells you where you are. Your history tells you where you’re heading. Upload your past lab reports and see this marker — and every marker on them —every marker charted against your own lab’s ranges.
Start with this report →
Healthmatters timeline preview showing biomarker trends over time

Frequently Asked Questions

What does the pattern on my ANA test mean?
The pattern describes how and where the antibodies stained the cells under a fluorescent microscope. It is a signpost — it may suggest which specific antibody to confirm next, but it usually does not identify which antibody is present, and it does not diagnose a disease on its own. Different patterns (homogeneous, speckled, nucleolar, centromere, cytoplasmic, mitotic) point toward different follow-up tests, which your clinician orders and reads together with your symptoms and titer. Some patterns suggest a fairly specific next test; several mitotic and cytoplasmic patterns have low predictive value.
What does a mitotic spindle fibers ANA pattern mean?
Mitotic spindle fibers (ICAP code AC-25) have a low positive predictive value for any disease and are found infrequently. The pattern reflects antibodies to the machinery cells use to divide. "Low predictive value" means the pattern does not point strongly toward a particular diagnosis — but it is not, by itself, evidence that disease is absent. Your clinician reads it together with your titer and symptoms rather than treating the pattern name, in either direction, as an answer. There is usually no routine confirmatory antibody test for it.
What does a cytoplasmic ANA pattern mean?
"Cytoplasmic" describes where the staining appeared — outside the nucleus — not one shared level of risk. Different cytoplasmic patterns point to different follow-up tests, so the exact AC code matters. Reticular/AMA (AC-21) suggests antimitochondrial antibodies and primary biliary cholangitis, a chronic liver condition. Dense fine speckled (AC-19) can suggest antibodies relevant to SLE, antisynthetase syndrome, or necrotizing myopathy; fine speckled (AC-20) can suggest anti-Jo-1, linked to antisynthetase syndrome and interstitial lung disease. Use the specific AC code on your report rather than reading "cytoplasmic" as a single result, and let your clinician order the matching follow-up test.
Does a positive ANA pattern mean I have lupus or an autoimmune disease?
Not by itself. A positive ANA can occur in several conditions and in healthy people. The pattern shows where staining occurred and may suggest which antibody to test for next; it does not identify the antibody or diagnose a disease. Your clinician interprets it with the titer, symptoms, examination, and any antibody-specific results.
What is the difference between the ANA titer and the pattern?
The titer is a ratio (like 1:80, 1:320, 1:640) — the endpoint dilution, showing how far the blood was diluted and still showed antibodies, a semiquantitative estimate of how much. The pattern is the shape and location of the staining, which suggests candidate antibodies to confirm. They are read together: a higher titer is generally more likely to be meaningful, while a low titer is common in healthy people — though the weight of a titer depends on the pattern. Neither alone is the answer.
What is a dense fine speckled (DFS70) pattern?
The dense fine speckled pattern (AC-2) is associated with an antibody called anti-DFS70. It is often described as reassuring, but that holds only under specific conditions: the pattern must be confirmed as a genuine DFS70 and not the newer AC-30 look-alike (which can be mistaken for it), the anti-DFS70 antibody must be the only relevant antinuclear antibody found, and clinical suspicion must already be low. When all three hold, it can lower suspicion for autoimmune rheumatic disease. The staining pattern alone is not enough — your clinician confirms it and reads it alongside your titer and symptoms.
Can my ANA pattern change over time?
Yes. The reported pattern can change between tests, and even between labs, because it depends on which antibodies are present and how a given laboratory reads the staining. A change in pattern is not automatically meaningful on its own — what matters is the pattern and titer read together with your symptoms and any specific antibody results. If your pattern changes, that is a question to raise with your clinician rather than a result to interpret alone.
Clinical Sources & References

All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.

  1. International Consensus on ANA Patterns (ICAP) — nomenclature and per-pattern clinical relevance (AC-1 to AC-31, plus AC-0 and AC-XX)
    International Consensus on ANA Patterns · 2019 View source ↗
  2. Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective
    Ann Rheum Dis. · 2019 View source ↗
  3. Primary Biliary Cholangitis Antibody Panel / AMA — cytoplasmic reticular/AMA (AC-21) as the serological hallmark of PBC
    Mayo Clinic Laboratories · 2026 View source ↗
  4. Current laboratory and clinical practices in reporting and interpreting ANA IIF patterns: an international survey
    Autoimmunity Highlights (2020) · 2020 View source ↗
  5. Uncommon patterns of antinuclear antibodies recognizing mitotic spindle apparatus antigens and clinical associations
    Medicine (Baltimore). · 2018 View source ↗
  6. ANA Screen,IFA, with Reflex to Titer and Pattern
    Quest Diagnostics test directory · 2026 View source ↗
  7. ANAlyzeR ANA, IFA with Reflex Titer/Pattern, Systemic Autoimmune Panel 1
    Quest Diagnostics · 2026 View source ↗
  8. Understand autoimmune screening results (autoimmune interpretation guide, SB12548)
    Quest Diagnostics interpretation guide (SB12548, 1/2024) · 2024 View source ↗
  9. ANA testing FAQ (FAQ177) — current screening dilution and pattern reporting
    Quest Diagnostics (current FAQ, version 4, effective 8 June 2026) · 2026 View source ↗
Article Review Log
Last reviewed July 23, 2026
Originally published July 23, 2026
Reviewed by HealthMatters Editorial Team
Written by Healthmatters Editorial Team
Healthmatters Lifetime Plan

Pay $250. Track your health forever

One payment. No renewals. Yours for life.

10,000+ biomarkers explained · trends over time

See other plans →
Secure checkout via Stripe · GDPR & HIPAA
We accept results from any lab
LabCorp Quest Diagnostics Genova Diagnostics DUTCH Test Doctor's Data Vibrant America ZRT Laboratory Cyrex Labs + any other lab

What members are saying

★★★★★ 10,000+ happy members
★★★★★

"Watching my numbers move over the years — instead of forgetting last time's results — completely changed how I manage my health."

Daniel
Member since 2022
★★★★★

"Living across several countries made keeping my lab results organized a real challenge. Healthmatters brought my results from the USA, Spain, and Germany together — 20 years of history, with long-term trends instead of scattered reports."

Ben
Member since 2021 · tracks across countries
★★★★★

"Standard lab ranges are too wide for how I practice — 'normal' isn't optimal. I set my own bands, so a client sees yellow before a marker goes officially out of range. That's the conversation I want to be having."

Dr. Alexandra
Functional medicine · 6 yrs on Pro